Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 25 May 2016 | By Michael Mezher
The Agency for Medicinal Products and Medical Devices of Croatia (HALMED) on Monday issued a statement of non-compliance to Indian active pharmaceutical ingredient (API) manufacturer Dhanuka Laboratories Ltd.
The notice was issued following an inspection of Dhanuka's Gurgaon, India facility conducted on 19 February 2016, during which inspectors discovered 32 good manufacturing practice (GMP) violations, including one critical violation involving Dhanuka's "weak" quality assurance (QA) system.
While the inspection was specifically linked to the manufacture of the antibiotic cefixime, HALMED says the issues uncovered related to the company's QA system could affect other products manufactured at the site, including the antibiotics cefdinir, cefuroxime and cefaclor.
"The QA system implemented on site, which related to the workshops that were engaged in the manufacture of cefixime, was found to be weak and not capable of proper design, planning, implementation, maintenance and continuous improvement of a system that allows the consistent delivery of products with appropriate quality attributes," the report states.
Due to the issues observed during the inspection, HALMED says EU regulators should consider removing the marketing authorization for affected Dhanuka products, and is banning the company from supplying further batches until the issues cited in the report are resolved.
Additionally, the European Dhanuka's certificate Directorate for the Quality of Medicines' (EDQM) Ad Hoc Committee has decided to suspend both cefixime (R1-CEP 2003-014-Rev 02) and cefuroxime axetil (R0-CEP 2011-173-Rev 00) based on the inspection findings.
Aside from the issues identified with Dhanuka's QA system, the inspectors cited the company for a number of other major GMP violations.
According to the inspectors, poor controls at the facility could have allowed for mix-ups of batches of cefixime that were derived from different production processes.
Inspectors also noted they could not rule out the possibility of product contamination in one of the centrifugation areas at the facility. "The rooms hosting the fluid bed dryers, as well as the dryers themselves, were found as not in accordance with [GMP] requirements because a contamination of the products openly handled in this area could not be excluded," the report states.
Additionally, the inspectors say they made "several observations with regard to the receipt, storage and dispensing of raw materials, key starting materials, intermediates and finished APIs … leading to the conclusion that a negative impact on quality cannot be excluded."
Lastly, the inspectors note that Dhanuka failed to implement a corrective and preventative action plan (CAPA) for observations related to the qualification of equipment at the facility made during a previous EDQM inspection. The inspectors say the company only addressed the qualification issues for specific equipment, rather than addressing the equipment qualification issues in a "holistic" manner.
Focus has reached out to Dhanuka for comment on the statement of non-compliance but the company has yet to respond.
EudraGMP
Tags: GMP, Good manufacturing practice, HALMED, Dhanuka Laboratories
Regulatory Focus newsletters
All the biggest regulatory news and happenings.